NY-ANTLER
13.10.2021 15:07:12 CEST | Business Wire | Press release
Global venture capital firm Antler has announced that it has closed over $300m to date, allowing it an opportunity to provide continued support to its companies in subsequent funding rounds. Investors in the funds include Schroders, Vækstfonden, and Phoenix Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005689/en/
Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people. The primary focus of the firm will remain investing at the pre-seed stage, with the firm now also having the ability to offer its portfolio companies follow-on capital as they grow and scale, up to Series C.
Magnus Grimeland, CEO and Founder of Antler, said “We continue to provide support for our founders from the earliest stages, and are thrilled to be able to continue investing in them as they grow. We look forward to backing even more entrepreneurs that are redefining industries in the future.”
Antler is continually developing and expanding its senior team, and its global presence. To this end, Antler has recruited new partners Naman Budhdeo, Erik Jonsson, Jiho Kang, and Subir Lohani to lead its new Canada, Vietnam, Korea, and Indonesia teams respectively.
Teddy Himler from SoftBank also joins as a Partner of the later-stage investment team.
Antler has invested in over 350 companies globally across over 30 different industries since 2018. Of these companies, 40% have at least one female co-founder, with 70 nationalities represented.
Antler continues to invest in its portfolio companies as they scale. The firm has a global network of over 600 expert advisors, and an online platform of resources, tools and supports its portfolio companies with introductions to global investors, hands-on assistance with new market entry, and access to a global network of expert advisors.
In providing continued support and investment, Antler confirms its position as a long-term partner for exceptional entrepreneurs -- from the outset of their journey, to the later stages as they scale.
Antler also intends to now invest in a number of companies from outside of its portfolio at seed and Series A stages. Antler has put together a team to oversee on-going investments, led by Antler partners: Martell Hardenberg, Co-Founder of Lazada; Teddy Himler, formerly of SoftBank; Stefan Jung, previously Managing Partner at Venturra Capital; and Navi Singh, a Researcher at MIT's Department of Mechanical Engineering.
This on-going evolution is built on what we believe to be a strong structural advantage in deal flow sourcing from regionally focused early-stage investments across 15 countries in 5 continents, including: Australia (Melbourne and Sydney), Canada (Toronto), Denmark (Copenhagen), Germany (Berlin), India (Bangalore), Indonesia (Jakarta), Kenya (Nairobi), Norway (Oslo), Sweden (Stockholm), Singapore, South Korea (Seoul), The Netherlands (Amsterdam), The UK (London), US (Austin and New York), and Vietnam (Ho Chi Minh).
Lieven Debruyne, Global Head of Distribution at Schroders said, “As a longstanding partner and investor in Antler, we are delighted to continue our investment in Antler. It is a unique opportunity to gain exposure to a global growth portfolio of innovative technology companies, and to ensure a steady stream of capital is being invested in companies that will define how we all live and work in the future”
Lars Nordal Jensen, Senior Director at Vækstfonden said, “We are thrilled to continue our commitment to Antler. We have previously invested in Antler, and have been delighted with the firm’s overwhelmingly positive contribution to the technology ecosystem since their market entry. In Vaekstfonden we want to help drive innovation and new technology, and therefore we are very pleased to see Antler continue its commitment to supporting innovative founders throughout their journey”
THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. NO OFFERING OF INTERESTS OF THE FUNDS REFERRED TO ABOVE HAS BEEN OR WILL BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY OTHER U.S. FEDERAL AND STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE UNITED STATES OR TO U.S. INVESTORS, UNLESS THEY ARE REGISTERED, OR EXEMPT FROM, OR NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT.
-ENDS-
About Antler
Antler is a global early-stage venture capital firm that invests in the defining technology companies of tomorrow. The firm has offices globally across most major entrepreneurial hubs, including in London, Berlin, Stockholm, New York, Singapore and Sydney.
Founded in Singapore in 2017, Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people, by building complementary co-founder teams, supporting the teams with deep business model validation and providing a global platform for scaling. To date, Antler has invested in over 350 companies globally across 30 different industries. Of these companies, 40% have at least one female co-founder, and the founders represent 70 nationalities. Antler’s current portfolio of startups includes: HomeBase , Reebelo , Qashier , Volopay , Pathzero , Marco Financial , Xanpool , PowerX , and Xailient .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005689/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 12:30:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 12:00:00 CEST | Press release
Aker BP joins as the first customer to scale agent-to-agent operations through a new generation of industrial agentic workflow applications Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 12:00:00 CEST | Press release
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data undersco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
